Загрузка...
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimu...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Libertas Academica
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2902205/ https://ncbi.nlm.nih.gov/pubmed/20711245 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|